Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637858 | 0.87 | SGMS2 (0.45) | KMT2ASGMS2 | |
| SCHEMBL7661916 | 0.86 | CASR (0.50) | CASRMTNR1AMTNR1BKMT2ATAAR1 | |
| SCHEMBL9111995 | 0.83 | TAAR1 (0.42) | CASRKMT2ATAAR1MAOB | |
| SCHEMBL27293617 | 0.83 | ESR2 (0.51) | KMT2ASLC6A4 | |
| SCHEMBL28611081 | 0.83 | ALDH1A1 (0.54) | KMT2A | |
| SCHEMBL29061992 | 0.81 | KMT2A (0.49) | CASRMTNR1AMTNR1BKMT2ATAAR1 | |
| SCHEMBL7652207 | 0.81 | KMT2A (0.49) | CASRMTNR1AMTNR1BKMT2ATAAR1 | |
| SCHEMBL7656005 | 0.81 | CASR (0.46) | CASRMTNR1AMTNR1BKMT2AMAOB | |
| SCHEMBL7652332 | 0.81 | CASR (0.46) | CASRMTNR1AMTNR1BKMT2AMAOB | |
| SCHEMBL31326036 | 0.81 | KMT2A (0.70) | MTNR1AMTNR1BKMT2AGPR139SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113713858-B | Alpha alkylation reaction catalyst of nitrile and preparation method thereof | 郑州大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-113559939-B | Alpha alkylation reaction catalyst of nitrile and preparation method thereof | 郑州大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-113713858-A | Alpha alkylation reaction catalyst of nitrile and preparation method thereof | 郑州大学 | 2021-11-30 | — | — | CN | disclosed |
| CN-113559939-A | Alpha alkylation reaction catalyst for nitrile and preparation method thereof | 郑州大学 | 2021-10-29 | — | — | CN | disclosed |
| CN-110026244-B | Alpha alkylation reaction catalyst of nitrile and application thereof | 郑州大学 | 2021-06-18 | — | — | CN | disclosed |
| US-9238619-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-8877794-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-11 | — | — | US | disclosed |
| EP-2603487-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012020130-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | CASR 2848/4885MTNR1A 1061/4885MTNR1B 923/4885 |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | CASR 2848/4885MTNR1A 1061/4885MTNR1B 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.